Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

Table 3

Patients survival data.

	Number (%)	1 year (%)	2 years (%)	5 years (%)	Median (mo, 95% CI)	value
Overall survival
All	126	93	77	54	88 (40–137)
DTH ≥ 15 mm	48 (40)	100	93	75	Not reached
DTH < 15 mm	71 (60)	89	70	44	45 (13–20)	<0001
DTH ≥ 10 mm	75 (63)	97	83	64	181 (75–287)
DTH < 10 mm	44 (37)	87	66	32	41 (23–59)	0.003
Disease-free survival
All	107	58	45	34	18 (5–31)
DTH ≥ 15 mm	36 (36)	74	53	47	36 (0.00–87)
DTH < 15 mm	65 (64)	55	42	26	15 (7–23)	0.27
Adjuvant radiotherapy; Overall survival
All	56	90	69	41	43 (27–59)	0.055
DTH ≥ 15 mm	22 (42)	100	87	58	111
DTH < 15 mm	31 (58)	84	56	33	31 (20–42)	0.024

DTH data was available for 119 of 126 patients.
DTH data was available for 101 of 107 patients with recorded disease-free survival.